Kazia Therapeutics (KZIA) Payables (2009 - 2025)

Kazia Therapeutics has reported Payables for 15 years, with the latest figure at $6.4 million in Q4 2025.

• For the quarter ending Q4 2025, Payables fell 7.68% year-over-year to $6.4 million; the trailing twelve-month figure through Dec 2025 stood at $6.4 million (down 7.68% YoY), and the FY2025 full-year result was $6.7 million, down 34.94% from the prior year.
• Payables for Q4 2025 stood at $6.4 million, down from $6.7 million in the prior quarter.
• The five-year high for Payables was $10.3 million in Q2 2024, with the low at $1.4 million in Q2 2022.
• Historically, Payables has averaged $5.1 million across 5 years, with a median of $4.4 million in 2021.
• Annual changes were most pronounced in 2022 — Payables sank 63.83% — and 2023, when it soared 197.98%.
• Kazia Therapeutics' Payables stood at $4.8 million in 2021, then tumbled by 48.97% to $2.4 million in 2022, then soared by 69.89% to $4.1 million in 2023, then jumped by 67.8% to $6.9 million in 2024, then fell by 7.68% to $6.4 million in 2025.
• The last three Payables figures came in at $6.4 million (Q4 2025), $6.7 million (Q2 2025), and $6.9 million (Q4 2024), per Business Quant data.